Last checked at 6 Apr 2020 07:00
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issuance of share options over ordinary shares of 0.2p each in the Company ("Share Options") to certain Directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP") established at the time of the Company's admission to AIM. These awards are made in accordance with the Company's long term incentive plan.
Share Options were granted as follows:
Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Grant date |
Peter Keeling, CEO | 180,000 | 180,000 | 0.26% | 3 April 2020 |
Philip White CFO | 180,000 | 180,000 | 0.26% | 3 April 2020 |
Ryan Keeling CIO | 180,000 | 180,000 | 0.26% | 3 April 2020 |
Damian Thornton COO and PDMR | 94,304 | 98,504 | 0.14% | 3 April 2020 |
Jordan Clark CCO and PDMR | 67,714 | 71,914 | 0.10% | 3 April 2020 |
Susanne Munksted PDMR | 62,272 | 66,472 | 0.10% | 3 April 2020 |
Other employees (72 persons with no individual in excess of 45,000 Share Options) | 665,955 | 825,555 | 1.19% | No later than 20 April 2020 |
The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 126.5p per share which has been calculated by using the average mid-market closing price over the past five business days.
Following the grant the total number of share options outstanding is 1,602,444, representing approximately 2.3% of the Company's current issued share capital of 69,583,100.
Enquiries:
Diaceutics PLC | www.diaceutics.com | ||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
Philip White, Chief Financial Officer |
| ||
|
| ||
Cenkos Securities plc (Nominated adviser and broker) | +44 (0)20 7397 8900 | ||
Callum Davidson / Giles Balleny |
| ||
Michael Johnson (Sales) |
| ||
|
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
About Diaceutics
Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Peter Keeling | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Executive Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 126.5p per share | 180,000 |
| |||||
| |||||||
e. | Date of the transaction | 3 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Philip White | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Financial Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 126.5p per share | 180,000 |
| |||||
| |||||||
e. | Date of the transaction | 3 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Ryan Keeling | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Information Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 126.5p per share | 180,000 |
| |||||
| |||||||
e. | Date of the transaction | 3 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Damian Thornton | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Operating Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 126.5p per share | 94,304 |
| |||||
| |||||||
e. | Date of the transaction | 3 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Jordan Clark | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Technology Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 126.5p per share | 67,714 |
| |||||
| |||||||
e. | Date of the transaction | 3 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Managing Director and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Grant of share options | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) | Volume(s) |
| ||||
Exercise price of 126.5p per share | 62,272 |
| |||||
| |||||||
e. | Date of the transaction | 3 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||